Crucible Therapeutics, an Argobio portfolio company, appoints Dr Cliff Holloway as new CEO
28/10/2025
PORTFOLIO NEWS: Welcome to Dr Cliff Holloway as new CEO of Crucible Therapeutics, founded by Argobio and focused on RNA-based therapies for ALS and neurodegenerative diseases.
Sheffield, UK – 28 October 2025 – Crucible Therapeutics, a biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Dr Cliff Holloway as Chief Executive Officer. Dr Holloway will also join the company’s Board of Directors.
“I am very pleased to welcome Cliff Holloway as our new CEO,” said Neill Moray Mackenzie, Executive Chairman of the Board and Entrepreneur-in-Residence at Argobio Studio. “Cliff brings extensive leadership experience from across the biotech and healthcare sectors and an impressive record of execution and value creation. His expertise and vision make him an ideal leader to guide Crucible into its next phase of growth.”
Commenting on his appointment, Dr Holloway said:“I’m thrilled to have the opportunity to lead Crucible and advance our programs towards delivering transformative therapies for patients with serious neurodegenerative diseases. I have a very personal mission to ensure Crucible’s success following the ALS diagnosis and passing of a very good friend and colleague just last year. Crucible’s novel RNA therapeutics represents an innovative approach to treating these devastating conditions and offers these patients much more than just hope. I look forward to working with our talented team and our world-class partners at the Sheffield Institute for Translational Neuroscience to drive our programs forward into the clinic and beyond.”
About Dr Cliff Holloway
Dr Cliff Holloway is an experienced biotechnology executive with over two decades of leadership in the sector. He was a former CEO, CBO and Director for several public and private biotechnology companies including Ethris GmbH, Scancell Holdings (AIM:SCLP), Benitec Biopharma, Biosceptre International, Immune Sytem Therapeutics, and Arana Therapeutics.
He has specialised in facilitating the growth, organisation, and culture of companies transitioning from the laboratory to the clinic by guiding teams through major clinical, regulatory, and development milestones. He has broad therapeutic development experience in a range of drug classes and modalities, with extensive experience in partnering of such assets from preclinical to clinical stage, including asset acquisition, in/out-licensing, and co-development. He has raised over £100m from private, strategic and institutional investors and established a strong global network within the investor/advisor, pharma and biotech communities. Dr Holloway holds a PhD in Medicinal Chemistry and a Bachelor of Pharmacy from the University of Nottingham, UK.
About Crucible Therapeutics
Crucible Therapeutics is a biopharmaceutical company developing innovative therapies to treat neurodegenerative diseases. Its lead siRNA program targets Amyotrophic Lateral Sclerosis (ALS), a progressive and fatal disorder that leads to the loss of motor neurons in the brain and spinal cord. Crucible was launched in 2023 with seed financing from Northern Gritstone and Argobio Studio and operational support from Argobio Studio. Crucible is a University of Sheffield spin-out based on the world-class science of Professors and co-founders Guillaume Hautbergue, Pamela Shaw and Mimoun Azzouz at the Sheffield Institute for Translational Neuroscience (SITraN) and the Sheffield National Institute for Health and Care Research Biomedical Research Centre (Sheffield NIHR BRC). For more information, please visit www.crucible-tx.com.
